Latest News

To evaluate the neurological safety and clinical efficacy of darifenacin and mirabegron in patients with a history of cerebrovascular accident (CVA) who had overactive bladder (OAB) symptoms. This prospective randomized study, approved by the institute’s ethics committee, was carried out at a tertiary care center from December 2018 to June 2020.

Neurogenic bladder dysfunction is a major source of urologic morbidity in children, especially in those with spina bifida (SB). Complications from progression of bladder dysfunction can include urinary tract infections (UTIs), urinary incontinence, upper tract deterioration, and renal dysfunction or failure.

Antimuscarinic drugs are the first-line choice in the treatment of patients with neurogenic Detrusor Overactivity (nDO). Fesoterodine fumarate is the newest antimuscarinic drug. Limited data are published about the use of fesoterodine fumarate in patients suffering from neurogenic lower urinary tract dysfunction.

The purpose of this systematic review was to investigate and synthesize the effects (benefits and harms) of electrical stimulation (EE), alone or in association with other interventions, compared with sham and other interventions, for the treatment of neurogenic bladder dysfunction in myelomeningocele.

Interstitial cystitis/bladder pain syndrome (IC/BPS) is not only a chronic urinary bladder pain syndrome but is also associated with multifactorial etiology. Our study aimed to test the hypothesis that IC/BPS is associated with subsequent increased risks of outpatient visits and hospitalizations.

(UroToday.com) Following the presentation from Dr. Armstrong of the final overall survival analysis of ARCHES examining the role of enzalutamide in metastatic castration sensitive prostate cancer (mCSPC), Dr. Oudard provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer […]

(UroToday.com) Following the presentation from Dr. Sandu of the preliminary results of the PRINCE trial of 177Lu-PSMA-617 in Combination with Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (mCRPC), Dr. Mateo provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. David McDermott discussing results of a phase 2 study of belzutifan + cabozantinib for the treatment of advanced clear cell renal cell carcinoma (RCC). HIF transcription activates several genes associated with clear cell RCC, including VEGF. […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Lisa Derosa discussing results of the phase 2 GETUG-AFU 26 NIVOREN trial and the impact of antibiotic therapy on outcomes. Previous studies have examined the impact of antibiotics on immune checkpoint inhibitor efficacy across a wide […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Giulia Baciarello discussing results from the phase 2 CABA-GCT trial. Men with advanced germ cell tumors with cancer progression after 2-3 lines of chemotherapy have a poor prognosis with currently no standard treatment. Taxanes have established […]